104 related articles for article (PubMed ID: 2698437)
21. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
Pillai G; Ellard GA; Smith PJ; Fourie PB
Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
Holland DP; Hamilton CD; Weintrob AC; Engemann JJ; Fortenberry ER; Peloquin CA; Stout JE
Pharmacotherapy; 2009 May; 29(5):503-10. PubMed ID: 19397460
[TBL] [Abstract][Full Text] [Related]
23. [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].
Brändli O; Dreher D; Morger D
Schweiz Med Wochenschr; 1993 Jun; 123(25):1300-6. PubMed ID: 8341998
[TBL] [Abstract][Full Text] [Related]
24. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
[TBL] [Abstract][Full Text] [Related]
25. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic study of the interaction between rifampicin and ketoconazole.
Doble N; Shaw R; Rowland-Hill C; Lush M; Warnock DW; Keal EE
J Antimicrob Chemother; 1988 May; 21(5):633-5. PubMed ID: 3391862
[TBL] [Abstract][Full Text] [Related]
27. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
[TBL] [Abstract][Full Text] [Related]
28. Study on drug interactions.
Venkatesan K; Bharadwaj VP; Ramu G; Desikan KV
Lepr India; 1980 Apr; 52(2):229-35. PubMed ID: 7453137
[TBL] [Abstract][Full Text] [Related]
29. Pyrazinamide serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
[TBL] [Abstract][Full Text] [Related]
30. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Teo SK
Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
[TBL] [Abstract][Full Text] [Related]
31. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.
Nijland HM; Ruslami R; Stalenhoef JE; Nelwan EJ; Alisjahbana B; Nelwan RH; van der Ven AJ; Danusantoso H; Aarnoutse RE; van Crevel R
Clin Infect Dis; 2006 Oct; 43(7):848-54. PubMed ID: 16941365
[TBL] [Abstract][Full Text] [Related]
32. [Simultaneous study of the induction effect of rifampicin and the phenotype for acetylation of isoniazid in 21 patients with tuberculosis undergoing a combination treatment].
Chailleux E; Ordronneau J; Le Normand Y; Kergueris MF; Larousse C
Rev Fr Mal Respir; 1980; 8(3):219-24. PubMed ID: 7187065
[TBL] [Abstract][Full Text] [Related]
33. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
[TBL] [Abstract][Full Text] [Related]
34. Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis.
Dubra F
Bull Int Union Tuberc; 1972 Feb; 47():37-40. PubMed ID: 4562016
[No Abstract] [Full Text] [Related]
35. [Results of examination in healthy volunteers of rifampicin and isoniazid bioavailability from Polish two-drug combination capsules of rifamazid used for tuberculosis treatment].
Zofia Z; Niemirowska-Mikulska H; Augustynowicz-Kopeć E; Stambrowska A
Pneumonol Alergol Pol; 1998; 66(3-4):198-206. PubMed ID: 9857665
[TBL] [Abstract][Full Text] [Related]
36. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
[No Abstract] [Full Text] [Related]
37. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.
Smith PJ; van Dyk J; Fredericks A
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S325-8; discussion S351-2. PubMed ID: 10593712
[TBL] [Abstract][Full Text] [Related]
38. Effect of oral administration of crude aqueous extract of garlic on pharmacokinetic parameters of isoniazid and rifampicin in rabbits.
Dhamija P; Malhotra S; Pandhi P
Pharmacology; 2006; 77(2):100-4. PubMed ID: 16699292
[TBL] [Abstract][Full Text] [Related]
39. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.
Acocella G; Bonollo L; Garimoldi M; Mainardi M; Tenconi LT; Nicolis FB
Gut; 1972 Jan; 13(1):47-53. PubMed ID: 5060669
[TBL] [Abstract][Full Text] [Related]
40. Serum concentrations and bioavailability of rifampicin and isoniazid in combination.
Garnham JC; Taylor T; Turner P; Chasseaud LF
Br J Clin Pharmacol; 1976 Oct; 3(5):897-902. PubMed ID: 973984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
